Premium
Retracted: Isosorbide mononitrate versus alendronate for postmenopausal osteoporosis
Author(s) -
Nabhan Ashraf F.,
Rabie Noha H.
Publication year - 2008
Publication title -
international journal of gynecology and obstetrics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.895
H-Index - 97
eISSN - 1879-3479
pISSN - 0020-7292
DOI - 10.1016/j.ijgo.2008.07.011
Subject(s) - medicine , isosorbide mononitrate , bone mineral , osteoporosis , randomized controlled trial , isosorbide dinitrate , urology , bone density
Objective To compare the effectiveness, safety, and affordability of isosorbide mononitrate with alendronate for postmenopausal osteoporosis. Methods A randomized controlled trial of 60 postmenopausal women with osteoporosis. Participants were randomly assigned to receive either 20 mg daily of isosorbide mononitrate or 70 mg weekly of alendronate for 12 months. Bone mineral density (BMD) was measured using dual X‐ray absorptiometry (DXA) at baseline and after 12 months. Results Both groups showed significant improvement in BMD. Isosorbide mononitrate yielded a comparable effect to alendronate for BMD and T‐score at the end of the follow‐up period. For BMD and T score the mean differences between the 2 groups were – 0.005 (95% CI, – 0.02 to 0.03) and 0.31 (95% CI, – 0.03 to 0.64), respectively. A 10.8% and 12.1% change in BMD after 12 months was seen for isosorbide mononitrate and alendronate, respectively. Conclusion Isosorbide mononitrate is comparable to alendronate. Nitric oxide donors may be an effective and affordable therapy to improve bone mineral density.